+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Rheumatoid Arthritis - Market Insights, Epidemiology and Market Forecast - 2030

  • ID: 5139011
  • Drug Pipelines
  • October 2020
  • Region: Global
  • 434 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • AbbVie
  • Aclaris Therapeutics
  • Genosco/Oscotec
  • GlaxoSmithKline
  • Izana Bioscience/Takeda
  • Mesoblast
  • MORE
This ‘Rheumatoid Arthritis (RA) - Market Insights, Epidemiology and Market Forecast - 2030’ report delivers an in-depth understanding of the RA, historical and forecasted epidemiology as well as the RA market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The RA market report provides current treatment practices, emerging drugs, RA market share of the individual therapies, current and forecasted RA market size from 2017 to 2030 segmented by seven major markets. The Report also covers current RA treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2017-2030

Rheumatoid Arthritis (RA): Disease Understanding and Treatment Algorithm

Rheumatoid Arthritis Overview

Rheumatoid arthritis (RA) is an autoimmune or chronic inflammatory disease that is known to impact the joints of the body adversely. An autoimmune disorder is a condition where the immune system starts making antinuclear bodies instead of antibodies which directs them to cause self-injury to the body, on the onset of disease, the immune response primarily attacks and harm the joints. RA is more common in women and about 75% of RA patients are women. Around 1 to 3% of women may get rheumatoid arthritis in their lifetime. The disease most often begins between the ages of 30 and 50. However, RA can start at any age.

Clinically, the symptoms of RA significantly differ between early-stage RA and insufficiently treated later stages of the disease. Early-stage RA is characterized by generalized disease symptoms such as fatigue, flu-like feeling, swollen and tender joints, and morning stiffness; and is paralleled by elevated levels of C-reactive protein (CRP) and an increased erythrocyte sedimentation rate (ESR). In contrast, insufficiently treated RA displays a complex clinical picture with the occurrence of serious systemic manifestations such as pleural effusions, lung nodules and interstitial lung disease, lymphomas, vasculitis in small or medium-sized arteries, keratoconjunctivitis, atherosclerosis, hematologic abnormalities (e.g., anemia, leukopenia, neutropenia, eosinophilia, thrombocytopenia, or thrombocytosis), joint misalignments, loss of range of motion, bone erosion, cartilage destruction, and rheumatic nodules. These systemic manifestations caused by the chronic inflammatory state in RA patients result in increased mortality.

Rheumatoid Arthritis Diagnosis

Typically, RA is diagnosed by a combination of patient’s symptoms, results of doctor´s examination, assessment of risk factors, family history, a joint assessment by ultrasound sonography, and assessment of laboratory markers such as elevated levels of CRP and ESR in serum and detection of RA-specific autoantibodies.

More than two thirds of RA patients have reported moderate to severe symptoms and having disease activity (DAS) score of 3.2 or above. And by this stage, most of the patients have joints that are experiencing swelling and pain and may have deformities, like malalignment, in some joints as a result of cartilage destruction.

RA Epidemiology

The RA epidemiology division provides the insights about historical and current RA patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

In the year 2017, the total prevalent cases of RA was 4,356,793 cases in the 7MM which are expected to grow during the study period, i.e., 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted RA epidemiology segmented as [Total Prevalent Cases of RA, Diagnosed cases of RA, Gender-specific cases of RA, Diagnosed cases of RA by Age Distribution, Severity-specific cases of RA, Patients on targeted therapies of RA, and Line-Wise Treated Cases of RA] scenario of RA in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- RA Epidemiology

Estimates show that the highest cases of RA in the 7MM were in the United States, followed by Japan, Germany, the United Kingdom, France, Italy, and Spain in 2017.
  • The United States, in 2017, accounted for 1,333,290 RA prevalent cases, which are expected to grow during the study period, i.e., 2017-2030.
  • In the year 2017, the total prevalent cases of RA in EU5 were 1,956,920, which are expected to grow during the study period, i.e., 2017-2030.
  • In the year 2017, the total prevalent cases of RA in Japan were 1,066,584, which are expected to grow during the study period, i.e., 2017-2030.
RA Drug Chapters

Drug chapter segment of the RA report encloses the detailed analysis of RA marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the RA clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

RA Approved Drugs

Olumiant/Baricitinib (Eli Lilly and Company/Incyte Corporation)
Rinvoq/Upadacitinib (AbbVie)
Xeljanz/Tofacitinib (Pfizer/PF Prism CV)
Remicade/Infliximab (Janssen Biotech/Centocor)
Enbrel/Etanercept (Immunex/Amgen)
MabThera/Rituxan/Rituximab (Genentech/Biogen)
Cimzia/Certolizumab-pegol (UCB)
Simponi/Golimumab (Jannsen Biotech)
Humira/Adalimumab (Abbvie)
Orencia/Abatacept (Bristol Myers Squibb)
Smyraf/Peficitinib (Astellas Pharma)
Actemra/Tocilizumab (Roche)
Kineret/Anakinra (Amgen/Swedish Orphan Biovitrum AB)
Kevzara/Sarilumab (Regeneron and Sanofi/Asahi Kasei Pharma)

Note:
Detailed Current therapies assessment will be provided in the full report of RA

RA Emerging Drugs

Otilimab/GSK3196165 (GlaxoSmithKline)
Filgotinib/GS-6034/GLPG0634/Jyseleca (Gilead and Galapagos NV)
Olokizumab (R Pharm)
Ozoralizumab/TS-152 (Taisho Pharmaceuticals/Ablynx)
ATI-450/CDD-450 (Aclaris Therapeutics)
VIB4920 (Viela Bio)
Branebrutinib (Bristol Myers Squibb)
ABBV-3373 and ABBV-154 (AbbVie)
Dekavil/F8IL10 (Pfizer/Philogen)
PF-06651600/Ritlecitinib (Pfizer)
JTE-051 (Akros Pharma/Japan Tobacco)
Evobrutinib/M2951 (Merck)
PF-06650833 (Pfizer)
Fenebrutinib/GDC-0853/RG7845 (Roche/Genentech)
MPC-300-IV/ Allogeneic Mesenchymal Precursor Cells (Mesoblast)
Bimekizumab (UCB Pharma/PRA HEALTH SCIENCES)
Namilumab/IZN-101/AMG203 (Izana Bioscience/Takeda)
ABX464 (Abivax)
HB-AdMSCs (Hope Biosciences)
SKI-O-703 (Genosco/Oscotec)

Note: Detailed emerging therapies assessment will be provided in the final report.

RA Market Outlook

RA is an autoimmune disease for which several effective treatment options are present. Currently, there are three primary treatment options for severe and advancing RA which include DMARDs, NSAIDs, and corticosteroids. Early treatment of RA patients with DMARDs significantly decreases these complications. Methotrexate is an excellent, economical first-line DMARD used to treat a majority of RA patients. While most patients respond well to MTX, many continue to have active disease.

DMARDs are immunosuppressive and immunomodulatory agents and are classified as either conventional DMARDs or biologic DMARDs. Biologic DMARDs are rapidly effective in retarding the progression of the joint damage caused by RA. Tumor necrosis factor (TNF) is a messenger protein that promotes inflammation in joints. Biologic medications such as Enbrel (etanercept), Remicade (infliximab), Humira (adalimumab), Simponi (golimumab), and Cimzia (certolizumab pegol) are all TNF inhibitors that prevent the recruitment of the cells that cause inflammation, bringing rapid symptom relief. It is worth noting that, prior to 2009, Enbrel, Remicade, and Humira were only three TNF inhibitors dominating the market of RA in the United States. Apart from this, T-cell costimulatory blocking agents (Orencia), B-cell depleting agents (Rituxan), interleukin-6 (IL-6) inhibitors (Actemra), and interleukin-1 (IL-1) receptor antagonists (Kineret), have also been approved over the past few years for the management of RA.

Companies like GlaxoSmithKline [Otilimab (MOR103/GSK3196165)], Taisho Pharmaceutical [Ozoralizumab (TS-152)], Gilead and Galapagos NV [Filgotinib (GS-6034; Jyseleca)], and R-Pharm (Olokizumab) with their key candidates are in registrational or late clinical-stage. In addition to this, companies like Merck KGaA (Evobrutinib), Pfizer (PF-06650833, and PF-06651600), Roche (Fenebrutinib), and several others in phase II clinical development stage with their investigational candidates.

In conclusion, it can be summarized that as many potential therapies are being investigated for the management of RA, it is safe to predict that the treatment space will experience a significant impact during the forecast period of 2020-2030.

Key Findings

The RA market size in the 7MM is expected to change during the study period 2017-2030. The therapeutic market of RA in the seven major markets was USD 21,184.4 million in 2017 which is expected to increase during study period (2017-2030). According to the estimates, the highest market size of RA is found in the United States followed by Japan and Germany.

The United States Market Outlook

In 2017, the total market size of RA therapies was USD 13,152 million in the United States which is expected to increase in the study period (2017-2030).

EU-5 Countries: Market Outlook

In 2017, the total market size of RA therapies was USD 5,038.2 million in the EU-5 countries which is expected to increase in the study period (2017-2030).

Japan Market Outlook

The total market size of RA therapies in Japan was USD 2,994.6 million in 2017 which is expected to increase in the study period (2017-2030).

RA Pipeline Development Activities

The drugs which are in pipeline include:

1. Otilimab/GSK3196165 (GlaxoSmithKline)
2. Filgotinib/GS-6034/GLPG0634/Jyseleca (Gilead and Galapagos NV)
3. Olokizumab (R Pharm)
4. Ozoralizumab/TS-152 (Taisho Pharmaceuticals/Ablynx)
5. ATI-450/CDD-450 (Aclaris Therapeutics)
6. VIB4920 (Viela Bio)
7. Branebrutinib (Bristol Myers Squibb)
8. ABBV-3373 and ABBV-154 (AbbVie)
9. Dekavil/F8IL10 (Pfizer/Philogen)
10. PF-06651600/Ritlecitinib (Pfizer)
11. JTE-051 (Akros Pharma/Japan Tobacco)
12. Evobrutinib/M2951 (Merck)
13. PF-06650833 (Pfizer)
14. Fenebrutinib/GDC-0853/RG7845 (Roche/Genentech)
15. MPC-300-IV/ Allogeneic Mesenchymal Precursor Cells (Mesoblast)
16. Bimekizumab (UCB Pharma/PRA HEALTH SCIENCES)
17. Namilumab/IZN-101/AMG203 (Izana Bioscience/Takeda)
18. ABX464 (Abivax)
19. HB-AdMSCs (Hope Biosciences)
20. SKI-O-703 (Genosco/Oscotec)

Note: Detailed emerging therapies assessment will be provided in the final report.

RA Drugs Uptake

Among the recently launched and upcoming therapies, upadacitinib and filgotinib has the potential to impact the market owing to more selective oral JAK1 inhibitor and better clinical profile compared to already approve JAKi. Although upadacitinib will have slight edge over filgotinib owing to order of entry and slightly better efficacy data.

Access and Reimbursement Scenario in RA Therapies

European League Against Rheumatism (EULAR) updated recommendations for the management of rheumatoid arthritis (RA) with synthetic and biologic disease-modifying antirheumatic drugs (DMARDs).

Leflunomide or sulfasalazine was considered as part of first-line treatment if patients experience early intolerance. Other conventional synthetic DMARDs in the absence of poor prognostic factors was recommended if the treatment target was not achieved after the first-line conventional synthetic DMARD strategy.

A biologic DMARD or a targeted synthetic DMARD was recommended if poor prognostic factors were present, and the treatment target was not achieved with the first conventional synthetic DMARD strategy. The targeted synthetic DMARDs include tofacitinib and baricitinib, synthetic DMARDs specifically designed to target Janus kinases.

EULAR recommended that biologic DMARDs and targeted synthetic DMARDs be combined with a conventional synthetic DMARD as all biologic and targeted synthetic DMARDs are more efficacious in combination therapy compared with monotherapy.

According to EULAR, if a biologic DMARD or targeted synthetic DMARD therapy fails, treatment with another biologic DMARD or targeted synthetic DMARD should be considered. Similarly, if treatment with tumor necrosis factor inhibitor (TNFi) fails, patients may be effectively treated with a different mode of action or a second TNFi therapy.

The National Institute for Health and Care Excellence has recommended Rinvoq, added to standard-of-care methotrexate, for coverage on the National Health Service as a treatment for severe rheumatoid arthritis in January 2020.

In the UK, Sarilumab with methotrexate, was recommended by NICE in 2017 as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs (DMARDs), only if:
  • The disease is severe (a disease activity score [DAS28] of more than 5.1) and
  • The company provides sarilumab with the discount agreed in the patient access scheme.
  • In 2018, an added benefit for Tofacitinib in combination with methotrexate after pretreatment with a conventional synthetic DMARD or with a biological DMARD was not proven for the treatment of adults who have had an inadequate response or who have been intolerant to a prior DMARD therapy by IQWIG, Germany.
  • In 2019, IQWIG reported hint of minor added benefit after pretreatment with a conventional synthetic DMARD for Tofacitinib in combination with methotrexate in adults who have had an inadequate response or who were intolerant to a prior DMARD therapy.
  • In 2017, IQWIG reported hint of an added benefit for Sarilumab in patients for whom treatment with biologic disease-modifying antirheumatic drugs (bDMARD) is indicated for the first time and who do not tolerate MTX. Added benefits were not proven for other patient groups.
Note: Detailed Access and Reimbursement Scenario will be provided in the final report.

KOL-Views

To keep up with current market trends, the publisher takes KOLs and SME’s opinion working in RA domain through primary research to fill the data gaps and validate The secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or RA market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

The publisher performs Competitive and Market Intelligence analysis of the RA Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
  • The report covers the descriptive overview of RA, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
  • Comprehensive insight has been provided into the RA epidemiology and treatment in the 7MM.
  • Additionally, an RA-inclusive account of both the current and emerging therapies for RA is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of RA market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global RA market.
Report Highlights
  • In the coming years, RA market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence RA R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for RA. Launch of emerging therapies, will significantly impact the RA market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for RA.
  • The in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
RA Report Insights
  • Patient Population
  • Therapeutic Approaches
  • RA Pipeline Analysis
  • RA Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
RA Report Key Strengths
  • 11 Years Forecast
  • 7MM Coverage
  • RA Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake
RA Report Assessment
  • SWOT Analysis
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Conjoint Analysis
  • Market Attractiveness
  • Market Drivers and Barriers
Key Questions

Market Insights:
  • What was the RA Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the RA total market size as well as market size by therapies across the 7MM during the study period (2017-2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest RA market size during the study period (2017-2030)?
  • At what CAGR, the RA market is expected to grow in the 7MM during the study period (2017-2030)?
  • What would be the RA market outlook across the 7MM during the study period (2017-2030)?
  • What would be the RA market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and a subsequent analysis of the associated trends?
  • RA patient types/pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
  • How emerging therapies are performing on the parameters like efficacy, safety, route of administration (RoA), treatment duration and frequencies on the basis of their clinical trial results?
  • Among the emerging therapies, what are the potential therapies which are expected to disrupt the RA market?
Epidemiology Insights:
  • What is the disease risk, burden and unmet needs of the RA?
  • What is the historical RA patient pool in the seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
  • What would be the forecasted patient pool of RA in the 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to RA?
  • Out of all the 7MM countries, which country would have the highest prevalent population of RA during the study period (2017-2030)?
  • At what CAGR the population is expected to grow in the 7MM during the study period (2017-2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of RA?
Current Treatment Scenario and Emerging Therapies:
  • What are the current options for the treatment of RA?
  • What are the current treatment guidelines for the treatment of RA in the US, Europe and Japan?
  • How many companies are developing therapies for the treatment of RA?
  • How many therapies are developed by each company for the treatment of RA?
  • How many emerging therapies are in mid stage, and late stage of development for the treatment of RA?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the RA therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for RA and their status?
  • What are the key designations that have been granted for the emerging therapies for RA?
  • What is the global historical and forecasted market of RA?
Reasons to buy
  • The report will help in developing business strategies by understanding trends shaping and driving the RA market.
  • To understand the future market competition in the RA market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for RA in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for RA market.
  • To understand the future market competition in the RA market.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie
  • Aclaris Therapeutics
  • Genosco/Oscotec
  • GlaxoSmithKline
  • Izana Bioscience/Takeda
  • Mesoblast
  • MORE
1. Key Insights

2. Executive Summary of Rheumatoid Arthritis (RA)

3. SWOT Analysis of RA

4. RA: Market Share (%) Distribution Overview at a Glance: By Country

5. RA: Market Share (%) Distribution Overview at a Glance: By Class

6. RA: Disease Background and Overview
6.1. Introduction
6.2. Stages of RA
6.3. Types of RA
6.3.1. Seropositive RA
6.3.2. Seronegative RA
6.4. Signs and Symptoms of RA
6.5. Risk Factors and Causes of RA
6.6. Complications of RA
6.7. Pathogenesis of RA
6.7.1. Disease Initiation
6.7.2. Triggers of Disease
6.7.3. Citrullination
6.7.4. Early and established RA
6.7.5. Propagation of Disease
6.8. Diagnosis of RA
6.9. Screening of RA
6.10. Rationale and Impact for investigations following the diagnosis: NICE 2020
6.11. Evaluations of Disease Activity in RA
6.12. American College of Rheumatology/European League against Rheumatism (ACR/EULAR) 2010 classification criteria for RA

7. Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM

8. Epidemiology Scenario: 7MM
8.1. Total Prevalent Cases of RA in the 7MM
8.2. Total Diagnosed Prevalent Cases of RA in the 7MM
8.3. Gender-specific Prevalent Cases of RA in the 7MM
8.4. Age-specific Prevalent Cases of RA in the 7MM
8.5. Severity-specific Prevalent Cases of RA in the 7MM
8.6. Patients on targeted therapies of RA in the 7MM
8.7. Line-Wise Treated Cases of RA in the 7MM

9. The United States Epidemiology
9.1. Total Prevalent Cases of RA in the United States
9.2. Total Diagnosed Prevalent Cases of RA in the United States
9.3. Gender-specific Prevalent Cases of RA in the United States
9.4. Age-specific Prevalent Cases of RA in the United States
9.5. Severity-specific Prevalent Cases of RA in the United States
9.6. Patients on targeted therapies of RA in the United States
9.7. Line-Wise Treated Cases of RA in the United States

10. EU-5 Epidemiology
10.1. Germany
10.1.1. Total Prevalent Cases of RA in Germany
10.1.2. Total Diagnosed Prevalent Cases of RA in Germany
10.1.3. Gender-specific Prevalent Cases of RA in Germany
10.1.4. Age-specific Prevalent Cases of RA in Germany
10.1.5. Severity-specific Prevalent Cases of RA in Germany
10.1.6. Patients on targeted therapies of RA in Germany
10.1.7. Line-Wise Treated Cases of RA in Germany
10.2. France
10.2.1. Total Prevalent Cases of RA in France
10.2.2. Total Diagnosed Prevalent Cases of RA in France
10.2.3. Gender-specific Prevalent Cases of RA in France
10.2.4. Age-specific Prevalent Cases of RA in France
10.2.5. Severity-specific Prevalent Cases of RA in France
10.2.6. Patients on targeted therapies of RA in France
10.2.7. Line-Wise Treated Cases of RA in France
10.3. Italy
10.3.1. Total Prevalent Cases of RA in Italy
10.3.2. Total Diagnosed Prevalent Cases of RA in Italy
10.3.3. Gender-specific Prevalent Cases of RA in Italy
10.3.4. Age-specific Prevalent Cases of RA in Italy
10.3.5. Severity-specific Prevalent Cases of RA in Italy
10.3.6. Patients on targeted therapies of RA in Italy
10.3.7. Line-Wise Treated Cases of RA in Italy
10.4. Spain
10.4.1. Total Prevalent Cases of RA in Spain
10.4.2. Total Diagnosed Prevalent Cases of RA in Spain
10.4.3. Gender-specific Prevalent Cases of RA in Spain
10.4.4. Age-specific Prevalent Cases of RA in Spain
10.4.5. Severity-specific Prevalent Cases of RA in Spain
10.4.6. Patients on targeted therapies of RA in Spain
10.4.7. Line-Wise Treated Cases of RA in Spain
10.5. The United Kingdom
10.5.1. Total Prevalent Cases of RA in the United Kingdom
10.5.2. Total Diagnosed Prevalent Cases of RA in the United Kingdom
10.5.3. Gender-specific Prevalent Cases of RA in the United Kingdom
10.5.4. Age-specific Prevalent Cases of RA in the United Kingdom
10.5.5. Severity-specific Prevalent Cases of RA in the United Kingdom
10.5.6. Patients on targeted therapies of RA in the United Kingdom
10.5.7. Line-Wise Treated Cases of RA in the United Kingdom

11. Japan Epidemiology
11.1. Total Prevalent Cases of RA in Japan
11.2. Total Diagnosed Prevalent Cases of RA in Japan
11.3. Gender-specific Prevalent Cases of RA in Japan
11.4. Age-specific Prevalent Cases of RA in Japan
11.5. Severity-specific Prevalent Cases of RA in Japan
11.6. Patients on targeted therapies of RA in Japan
11.7. Line-Wise Treated Cases of RA in Japan

12. Current Treatment Practices: RA
12.1. Medications
12.1.1. Conventional Disease-modifying antirheumatic drugs (DMARDs)
12.1.2. Biological treatments
12.1.3. JAK inhibitors
12.1.4. Analgesics and Non-steroidal anti-inflammatory drugs (NSAIDs)
12.1.5. Steroids
12.2. Supportive Treatment
12.2.1. Physiotherapy
12.2.2. Occupational therapy
12.2.3. Podiatry
12.3. Surgery
12.4. Treatment Algorithm
12.5. Guideline of RA
12.5.1. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019
12.5.2. NICE Recommendation: Drug treatment for rheumatoid arthritis
12.5.3. American College of Rheumatology Updated Guideline for the Management of Rheumatoid Arthritis: 2018

13. Unmet Needs

14. Patient Journey of RA

15. Key Endpoints in RA Clinical Trials

16. Marketed Therapies
16.1. Marketed Therapies Key Cross
16.2. Olumiant (Barticinib): Eli Lilly and Company/Incyte Corporation
16.2.1. Product Description
16.2.2. Regulatory Milestones
16.2.3. Other Developmental Activities
16.2.4. Pivotal Clinical Trial
16.3. Rinvoq (Upadacitinib): AbbVie
16.3.1. Product Description
16.3.2. Regulatory Milestones
16.3.3. Other Developmental Activities
16.3.4. Pivotal Clinical Trial
16.3.5. Ongoing Current Clinical Pipeline Activity
16.4. Xeljanz (Tofacitinib): Pfizer/PV PRISM CV
16.4.1. Product Description
16.4.2. Regulatory Milestones
16.4.3. Other developmental activities
16.4.4. Pivotal Clinical Trials
16.5. Remicade (Infliximab): Janssen Biotech (Centocor)
16.5.1. Product Description
16.5.2. Regulatory Milestones
16.5.3. Other Developmental Activities
16.5.4. Pivotal Clinical Trials
16.6. Enbrel (Etanercept): Immunex/Amgen
16.6.1. Product Description
16.6.2. Regulatory Milestones
16.6.3. Other developmental activities
16.6.4. Pivotal Clinical Trials
16.7. Rituxan/MabThera (Rituximab): Genentech/Biogen
16.7.1. Product Description
16.7.2. Regulatory Milestones
16.7.3. Other Developmental Activities
16.7.4. Pivotal Clinical Trials
16.8. Certolizumab-pegol (Cimzia): UCB Inc.
16.8.1. Product Description
16.8.2. Regulatory Milestones
16.8.3. Other Developmental Activities
16.8.4. Pivotal Clinical Trials
16.9. Golimumab (Simponi): Janssen Biotech
16.9.1. Product Description
16.9.2. Regulatory Milestones
16.9.3. Other Developmental Activities
16.9.4. Pivotal Clinical Trials
16.10. Humira (adalimumab): AbbVie
16.10.1. Product Description
16.10.2. Regulatory Milestones
16.10.3. Other Developmental Activities
16.10.4. Pivotal Clinical Trials
16.11. Orencia (Abatacept): Bristol Myers Squibb
16.11.1. Product Description
16.11.2. Regulatory Milestones
16.11.3. Other Developmental Activities
16.11.4. Pivotal Clinical Trials
16.12. Smyraf (Peficitinib): Astella Pharma
16.12.1. Product Description
16.12.2. Regulatory Milestones
16.12.3. Other Developmental Activities
16.12.4. Pivotal Clinical Trials
16.12.5. Ongoing Current Pipeline Activity
16.13. Actemra (Tocilizumab): Roche
16.13.1. Product Description
16.13.2. Regulatory Milestones
16.13.3. Other Developmental Activities
16.13.4. Pivotal Clinical Trial
16.13.5. Ongoing Current Pipeline Activity
16.14. Kineret (Anakinra): Swedish Orphan Biovitrium (SOBI)
16.14.1. Product Description
16.14.2. Regulatory Milestones
16.14.3. Other Developmental Activities
16.14.4. Pivotal Clinical Trial
16.15. Kevzara (Sarilumab): Regeneron and Sanofi
16.15.1. Product Description
16.15.2. Regulatory Milestones
16.15.3. Other Developmental Activities
16.15.4. Pivotal Clinical Trial

17. Emerging Therapies
17.1. Key Cross
17.2. GSK3196165 (otilimab/MOR103): GlaxoSmithKline
17.2.1. Product Description
17.2.2. Other Developmental Activities
17.2.3. Clinical Development
17.2.4. Safety and Efficacy
17.3. Filgotinib (GS-6034; GLPG0634; Jyseleca): Gilead and Galapagos NV
17.3.1. Product Description
17.3.2. Other Developmental Activities
17.3.3. Clinical Development
17.3.4. Safety and Efficacy
17.4. Olokizumab: R-Pharm
17.4.1. Product Description
17.4.2. Other Developmental Activities
17.4.3. Clinical Development
17.4.4. Safety and Efficacy
17.5. TS-152 (Ozoralizumab): Taisho Pharmaceuticals
17.5.1. Product Description
17.5.2. Other Developmental Activities
17.5.3. Clinical Development
17.5.4. Safety and Efficacy
17.6. ATI-450 (CDD-450): Aclaris Therapeutics
17.6.1. Product Description
17.6.2. Other Developmental Activities
17.6.3. Clinical Development
17.6.4. Safety and Efficacy
17.7. VIB4920: Viela Bio
17.7.1. Product Description
17.7.2. Other developmental activities
17.7.3. Clinical development
17.7.4. Safety and Efficacy
17.8. Branebrutinib: Bristol Myers Squibb
17.8.1. Product Description
17.8.2. Clinical development
17.8.3. Safety and efficacy
17.9. ABBV-3373 and ABBV-154: AbbVie
17.9.1. Product Description
17.9.2. Other Developmental Activities
17.9.3. Clinical Development
17.9.4. Safety and Efficacy
17.10. Dekavil (F8IL10): Pfizer/Philogen
17.10.1. Product Description
17.10.2. Other Developmental Activities
17.10.3. Clinical Development
17.10.4. Safety and Efficacy
17.11. PF-06651600 (Ritlecitinib): Pfizer
17.11.1. Product Description
17.11.2. Clinical Development
17.11.3. Safety and Efficacy
17.12. JTE 051: Akros Pharma/Japan Tobacco
17.12.1. Product Description
17.12.2. Other Developmental Activities
17.12.3. Clinical Development
17.13. Evobrutinib (M2951): Merck KGaA
17.13.1. Product Description
17.13.2. Clinical Development
17.14. PF-06650833: Pfizer
17.14.1. Product Description
17.14.2. Clinical Development
17.14.3. Safety and Efficacy
17.15. Fenebrutinib (GDC-0853, RG7845): Genentech (subsidiary of Roche)
17.15.1. Product Description
17.15.2. Other Developmental Activities
17.15.3. Clinical Development
17.15.4. Safety and Efficacy
17.16. MPC-300-IV (Allogeneic Mesenchymal Precursor Cells): Mesoblast
17.16.1. Product Description
17.16.2. Other Developmental Activities
17.16.3. Clinical Development
17.16.4. Safety and Efficacy
17.17. Bimekizumab: UCB Pharma/PRA HEALTH SCIENCES
17.17.1. Product Description
17.17.2. Other Developmental Activities
17.17.3. Clinical Development
17.17.4. Safety and Efficacy
17.18. Namilumab (IZN-101; AMG203): Izana Bioscience/Takeda
17.18.1. Product Description
17.18.2. Other Developmental Activities
17.18.3. Clinical Development
17.18.4. Safety and Efficacy
17.19. ABX464: Abivax S.A.
17.19.1. Product Description
17.19.2. Other Developmental Activities
17.19.3. Clinical Development
17.20. HB-AdMSCs: Hope Biosciences
17.20.1. Product Description
17.20.2. Clinical Development
17.21. SKI-O-703: Genosco (Oscotec)
17.21.1. Product Description
17.21.2. Other Developmental Activities
17.21.3. Clinical Development

18. Conjoint Analysis of RA

19. Rheumatoid Arthritis (RA): Seven Major Market Analysis
19.1. Key Findings
19.2. Market Outlook: 7MM

20. 7MM Market Size
20.1. Total Market Size of Rheumatoid Arthritis in the 7MM
20.2. Total Market size of Rheumatoid Arthritis by therapies in the 7MM

21. United States Market Size
21.1. Total Market size of Rheumatoid Arthritis in the United States
21.2. Total Market size of Rheumatoid Arthritis by Therapies in the United States

22. EU-5 Market Size
22.1. Germany Market Size
22.1.1. Total Market size of Rheumatoid Arthritis in Germany
22.1.2. Total Market size of Rheumatoid Arthritis by Therapies in Germany
22.2. France Market Size
22.2.1. Total Market size of Rheumatoid Arthritis in France
22.2.2. Total Market size of Rheumatoid Arthritis by Therapies in France
22.3. Italy Market Size
22.3.1. Total Market size of Rheumatoid Arthritis in Italy
22.3.2. Total Market size of Rheumatoid Arthritis by Therapies in Italy
22.4. Spain Market Size
22.4.1. Total Market size of Rheumatoid Arthritis in Spain
22.4.2. Total Market size of Rheumatoid Arthritis by Therapies in Spain
22.5. United Kingdom Market Size
22.5.1. Total Market size of Rheumatoid Arthritis in the United Kingdom
22.5.2. Total Market size of Rheumatoid Arthritis by Therapies in the United Kingdom

23. Japan Market Size
23.1. Total Market size of Rheumatoid Arthritis in Japan
23.2. Total Market size of Rheumatoid Arthritis by Therapies in Japan

24. Market Access and Reimbursement of RA Therapies
24.1. European League Against Rheumatism (EULAR) Recommendations
24.2. NICE Recommendations
24.3. American College of Rheumatology (ACR) Recommendations
24.4. Access and Reimbursement of Other Therapies
24.5. Recent Access and Recommendations of RA Therapies
24.6. Reimbursement Management

25. Market Drivers of RA

26. Market Barriers of RA

27. Appendix
27.1. Bibliography
27.2. Report Methodology

28. Publisher Capabilities

29. Disclaimer

30. About the Publisher

List of Tables
Table 1: Summary of Rheumatoid Arthritis (RA) Market, Epidemiology, and Key Events (2017–2030)
Table 2: Total Prevalent Cases of RA in the 7MM (2017–2030)
Table 3: Total Diagnosed Prevalent Cases of RA in the 7MM (2017–2030)
Table 4: Gender-specific Prevalent Cases of RA in the 7MM (2017–2030)
Table 5: Age-specific Prevalent Cases of RA in the 7MM (2017–2030)
Table 6: Severity-specific Prevalent Cases of RA in the 7MM (2017–2030)
Table 7: Total Patients on targeted therapies of RA in the 7MM (2017–2030)
Table 8: Line-Wise Treated Cases of RA in the 7MM (2017–2030)
Table 9: Total Prevalent Cases of RA in the United States (2017–2030)
Table 10: Total Diagnosed Prevalent Cases of RA in the United States (2017–2030)
Table 11: Gender-specific Prevalent Cases of RA in the United States (2017–2030)
Table 12: Age-specific Prevalent Cases of RA in the United States (2017–2030)
Table 13: Severity-specific Prevalent Cases of RA in the United States (2017–2030)
Table 14: Patients on targeted therapies of RA in the United States (2017–2030)
Table 15: Line-Wise Treated Cases of RA in the United States (2017–2030)
Table 16: Total Prevalent Cases of RA in Germany (2017–2030)
Table 17: Total Diagnosed Prevalent Cases of RA in Germany (2017–2030)
Table 18: Gender-specific Prevalent Cases of RA in Germany (2017–2030)
Table 19: Age-specific Prevalent Cases of RA in Germany (2017–2030)
Table 20: Severity-specific Prevalent Cases of RA in Germany (2017–2030)
Table 21: Patients on targeted therapies of RA in Germany (2017–2030)
Table 22: Line-Wise Treated Cases of RA in Germany (2017–2030)
Table 23: Total Prevalent Cases of RA in France (2017–2030)
Table 24: Total Diagnosed Prevalent Cases of RA in France (2017–2030)
Table 25: Gender-specific Prevalent Cases of RA in France (2017–2030)
Table 26: Age-specific Prevalent Cases of RA in France (2017–2030)
Table 27: Severity-specific Prevalent Cases of RA in France (2017–2030)
Table 28: Patients on targeted therapies of RA in France (2017–2030)
Table 29: Line-Wise Treated Cases of RA in France (2017–2030)
Table 30: Total Prevalent Cases of RA in Italy (2017–2030)
Table 31: Total Diagnosed Prevalent Cases of RA in Italy (2017–2030)
Table 32: Gender-specific Prevalent Cases of RA in Italy (2017–2030)
Table 33: Age-specific Prevalent Cases of RA in Italy (2017–2030)
Table 34: Severity-specific Prevalent Cases of RA in Italy (2017–2030)
Table 35: Patients on targeted therapies of RA in Italy (2017–2030)
Table 36: Line-Wise Treated Cases of RA in Italy (2017–2030)
Table 37: Total Prevalent Cases of RA in Spain (2017–2030)
Table 38: Total Diagnosed Prevalent Cases of RA in Spain (2017–2030)
Table 39: Gender-specific Prevalent Cases of RA in Spain (2017–2030)
Table 40: Age-specific Prevalent Cases of RA in Spain (2017–2030)
Table 41: Severity-specific Prevalent Cases of RA in Spain (2017–2030)
Table 42: Patients on targeted therapies of RA in Spain (2017–2030)
Table 43: Line-Wise Treated Cases of RA in Spain (2017–2030)
Table 44: Total Prevalent Cases of RA in the United Kingdom (2017–2030)
Table 45: Total Diagnosed Prevalent Cases of RA in the United Kingdom (2017–2030)
Table 46: Gender-specific Prevalent Cases of RA in the United Kingdom (2017–2030)
Table 47: Age-specific Prevalent Cases of RA in the United Kingdom (2017–2030)
Table 48: Severity-specific Prevalent Cases of RA in the United Kingdom (2017–2030)
Table 49: Patients on targeted therapies of RA in the United Kingdom (2017–2030)
Table 50: Line-Wise Treated Cases of RA in the United Kingdom (2017–2030)
Table 51: Total Prevalent Cases of RA in Japan (2017–2030)
Table 52: Total Diagnosed Prevalent Cases of RA in Japan (2017–2030)
Table 53: Gender-specific Prevalent Cases of RA in Japan (2017–2030)
Table 54: Age-specific Prevalent Cases of RA in Japan (2017–2030)
Table 55: Severity-specific Prevalent Cases of RA in Japan (2017–2030)
Table 56: Patients on targeted therapies of RA in Japan (2017–2030)
Table 57: Line-Wise Treated Cases of RA in Japan (2017–2030)
Table 58: Examples of painkillers and NSAIDs
Table 59: Key Cross of Marketed Therapies
Table 60: Upadacitinib; Clinical Trial Description;2020
Table 61: Peficitinib (Smyraf): Astella ; Clinical Trial Description, 2020
Table 62 :Actemra, Clinical Trial Description, 2020
Table 63: Key Cross of Emerging Therapies
Table 64: Otilimab, Clinical Trial Description, 2020
Table 65: Filgotinib, Clinical Trial Description, 2020
Table 66: Olokizumab, Clinical Trial Description, 2020
Table 67: Ozoralizumab, Clinical Trial Description, 2020
Table 68: ATI-450, Clinical Trial Description, 2020
Table 69: VIB4920, Clinical Trial Description, 2020
Table 70: Branebrutinib, Clinical Trial Description, 2020
Table 71: ABBV-3373, Clinical Trial Description, 2020
Table 72: Dekavil, Clinical Trial Description, 2020
Table 73: PF-06651600, Clinical Trial Description, 2020
Table 74: JTE-051;Clinical Trial Description, 2020
Table 75: Evobrutinib, Clinical Trial Description, 2020
Table 76: PF-06650833, Clinical Trial Description, 2020
Table 77: Fenebrutinib, Clinical Trial Description, 2020
Table 78: MPC-300-IV, Clinical Trial Description, 2020
Table 79: Bimekizumab, Clinical Trial Description, 2020
Table 80: Namilumab; Clinical Trial Description, 2020
Table 81: ABX464, Clinical Trial Description, 2020
Table 82: HB-AdMSCs; Clinical Trial Description, 2020
Table 83: SKI-O-703, Clinical Trial Description, 2020
Table 84: 7MM Market Size of Rheumatoid Arthritis, in USD Million (2017–2030)
Table 85: 7MM Market Size of Rheumatoid Arthritis by Class, in USD Million (2017–2030)
Table 86: 7MM Market Size of Rheumatoid Arthritis by Therapies, in USD Million (2017–2030)
Table 87: The United States Market Size of Rheumatoid Arthritis by Class, in USD Million (2017–2030)
Table 88: The United States Market Size of Rheumatoid Arthritis by Therapies, in USD Million (2017–2030)
Table 89: Germany Market Size of Rheumatoid Arthritis by Class, in USD Million (2017–2030)
Table 90: Germany Market Size of Rheumatoid Arthritis by Therapies, in USD Million (2017–2030)
Table 91: France Market Size of Rheumatoid Arthritis by Class, in USD Million (2017–2030)
Table 92: France Market Size of Rheumatoid Arthritis by Therapies, in USD Million (2017–2030)
Table 93: Italy Market Size of Rheumatoid Arthritis by Class, in USD Million (2017–2030)
Table 94: Italy Market Size of Rheumatoid Arthritis by Therapies, in USD Million (2017–2030)
Table 95: Spain Market Size of Rheumatoid Arthritis by Class, in USD Million (2017–2030)
Table 96: Spain Market Size of Rheumatoid Arthritis by Therapies, in USD Million (2017–2030)
Table 97: The United Kingdom Market Size of Rheumatoid Arthritis by Class, in USD Million (2017–2030)
Table 98: The United Kingdom Market Size of Rheumatoid Arthritis by Therapies, in USD Million (2017–2030)
Table 99: Japan Market Size of Rheumatoid Arthritis by Class, in USD Million (2017–2030)
Table 100: Japan Market Size of Rheumatoid Arthritis by Therapies, in USD Million (2017–2030)
Table 101: DMARD (Refers to any csDMARD, boDMARD, or tsDMARD) group
Table 102: Key HTA decisions for RA Therapies

List of Figures
Figure 1: RA SWOT Analysis
Figure 2: Rheumatoid Arthritis (RA) Distressed Area
igure 3: Stages of Rheumatoid Arthritis
Figure 4: Bone joint differentiation of normal and RA
Figure 5: Development and progression of RA
Figure 6: Types of Rheumatoid Arthritis
Figure 7: Sign and Symptoms of RA
Figure 8: Boggy swelling in proximal interphalangeal and metacarpophalangeal joints (more prominent on the patient’s right hand) in a patient with new-onset RA
Figure 9: Factors contributing to RA development
Figure 10: Associations and links for RA
Figure 11: Initiation and Progression of RA
Figure 12: Clinical manifestations of RA
Figure 13: Antinuclear Antibody Test
Figure 14: Clinical Diagnosis of RA
Figure 15: Diagnostic criteria for RA
Figure 16: Screening for Rheumatoid Arthritis
Figure 17: Total Prevalent Cases of RA in the 7MM (2017–2030)
Figure 18: Total Diagnosed Prevalent Cases of RA in the 7MM (2017–2030)
Figure 19: Gender-specific Prevalent Cases of RA in the 7MM (2017–2030)
Figure 20: Age-specific Prevalent Cases of RA in the 7MM (2017–2030)
Figure 21: Severity-specific Prevalent Cases of RA in the 7MM (2017–2030)
Figure 22: Patients on targeted therapies of RA in the 7MM (2017–2030)
Figure 23: Line-Wise Treated Cases of RA in the 7MM (2017–2030)
Figure 24: Total Prevalent Cases of RA in the United States (2017–2030)
Figure 25: Total Diagnosed Prevalent Cases of RA in the United States (2017–2030)
Figure 26: Gender-specific Prevalent Cases of RA in the United States (2017–2030)
Figure 27: Age-specific Prevalent Cases of RA in the United States (2017–2030)
Figure 28: Severity-specific Prevalent Cases of RA in the United States (2017–2030)
Figure 29: Patients on targeted therapies of RA in the United States (2017–2030)
Figure 30: Line-Wise Treated Cases of RA in the United States (2017–2030)
Figure 31: Total Prevalent Cases of RA in Germany (2017–2030)
Figure 32: Diagnosed Prevalent Cases of RA in Germany (2017–2030)
Figure 33: Gender-specific Prevalent Cases of RA in Germany (2017–2030)
Figure 34: Age-specific Prevalent Cases of RA in Germany (2017–2030)
Figure 35: Severity-specific Prevalent Cases of RA in Germany (2017–2030)
Figure 36: Patients on targeted therapies of RA in Germany (2017–2030)
Figure 37: Line-Wise Treated Cases of RA in Germany (2017–2030)
Figure 38: Total Prevalent Cases of RA in France (2017–2030)
Figure 39: Diagnosed Prevalent Cases of RA in France (2017–2030)
Figure 40: Gender-specific Prevalent Cases of RA in France (2017–2030)
Figure 41: Age-specific Prevalent Cases of RA in France (2017–2030)
Figure 42: Severity-specific Prevalent Cases of RA in France (2017–2030)
Figure 43: Patients on targeted therapies of RA in France (2017–2030)
Figure 44: Line-Wise Treated Cases of RA in France (2017–2030)
Figure 45: Total Prevalent Cases of RA in Italy (2017–2030)
Figure 46: Total Diagnosed Prevalent Cases of RA in Italy (2017–2030)
Figure 47: Gender-specific Prevalent Cases of RA in Italy (2017–2030)
Figure 48: Age-specific Prevalent Cases of RA in Italy (2017–2030)
Figure 49: Severity-specific Prevalent Cases of RA in Italy (2017–2030)
Figure 50: Patients on targeted therapies of RA in Italy (2017–2030)
Figure 51: Line-Wise Treated Cases of RA in Italy (2017–2030)
Figure 52: Total Prevalent Cases of RA in Spain (2017–2030)
Figure 53: Total Diagnosed Prevalent Cases of RA in Spain (2017–2030)
Figure 54: Gender-specific Prevalent Cases of RA in Spain (2017–2030)
Figure 55: Age-specific Prevalent Cases of RA in Spain (2017–2030)
Figure 56: Severity-specific Prevalent Cases of RA in Spain (2017–2030)
Figure 57: Patients on targeted therapies of RA in Spain (2017–2030)
Figure 58: Line-Wise Treated Cases of RA in Spain (2017–2030)
Figure 59: Total Prevalent Cases of RA in the United Kingdom (2017–2030)
Figure 60: Total Diagnosed Prevalent Cases of RA in the United Kingdom (2017–2030)
Figure 61: Gender-specific Prevalent Cases of RA in the United Kingdom (2017–2030)
Figure 62: Age-specific Prevalent Cases of RA in the United Kingdom (2017–2030)
Figure 63: Severity-specific Prevalent Cases of RA in the United Kingdom (2017–2030)
Figure 64: Patients on targeted therapies of RA in the United Kingdom (2017–2030)
Figure 65: Line-Wise Treated Cases of RA in the United Kingdom (2017–2030)
Figure 66: Total Prevalent Cases of RA in Japan (2017–2030)
Figure 67: Total Diagnosed Prevalent Cases of RA in Japan (2017–2030)
Figure 68: Gender-specific Prevalent Cases of RA in Japan (2017–2030)
Figure 69: Age-specific Prevalent Cases of RA in Japan (2017–2030)
Figure 70: Severity-specific Prevalent Cases of RA in Japan (2017–2030)
Figure 71: Patients on targeted therapies of RA in Japan (2017–2030)
Figure 72: Line-Wise Treated Cases of RA in Japan (2017–2030)
Figure 73: Treatment Overview of RA
Figure 74: Molecular mode of action of Janus activated kinase (JAK) inhibitors Tofacitinib and Baricitinib
Figure 75: Recommendations for the treatment of early rheumatoid arthritis (RA), defined as a disease duration of < 6 months
Figure 76: Treatment algorithm for established RA ( >6 months )
Figure 77: EULAR RA management recommendations in the form of an algorithm
Figure 78: Unmet Needs of Rheumatoid Arthritis
Figure 79: Mechanism of Action of Otilimab
Figure 80: Mechanism of Action of Olokizumab
Figure 81: Mechanism of Action of Ozoralizumab
Figure 82: Mechanism of Action of IL-10 pathway
Figure 83: Market Size of Rheumatoid Arthritis in the 7MM, in USD Billion (2017–2030)
Figure 84: Market Size of Rheumatoid Arthritis in the 7MM by Class, in USD Billion (2017–2030)
Figure 85: Market Size of Rheumatoid Arthritis in the 7MM by Therapies, in USD Billion (2017–2030)
Figure 86: Market Size of Rheumatoid Arthritis in the United States by Class, in USD Billion (2017–2030)
Figure 87: Market Size of Rheumatoid Arthritis in the United States by Therapy, in USD Billion (2017–2030)
Figure 88: Market Size of Rheumatoid Arthritis in Germany by Class, in USD Billion (2017–2030)
Figure 89: Market Size of Rheumatoid Arthritis in Germany by Therapy, in USD Billion (2017–2030)
Figure 90: Market Size of Rheumatoid Arthritis in France by Class, in USD Billion (2017–2030)
Figure 91: Market Size of Rheumatoid Arthritis in France by Therapy, in USD Billion (2017–2030)
Figure 92: Market Size of Rheumatoid Arthritis in Italy by Class, in USD Billion (2017–2030)
Figure 93: Market Size of Rheumatoid Arthritis in Italy by Therapy, in USD Billion (2017–2030)
Figure 94: Market Size of Rheumatoid Arthritis in Spain by Class, in USD Billion (2017–2030)
Figure 95: Market Size of Rheumatoid Arthritis in Spain by Therapy, in USD Billion (2017–2030)
Figure 96: Market Size of Rheumatoid Arthritis in the United Kingdom by Class, in USD Billion (2017–2030)
Figure 97: Market Size of Rheumatoid Arthritis in the United Kingdom by Therapy, in USD Billion (2017–2030)
Figure 98: Market Size of Rheumatoid Arthritis in Japan by Class, in USD Billion (2017–2030)
Figure 99: Market Size of Rheumatoid Arthritis in Japan by Therapy, in USD Billion (2017–2030)
Figure 100: Market Drivers of Rheumatoid Arthritis
Figure 101: Market barriers of Rheumatoid Arthritis
Note: Product cover images may vary from those shown
3 of 3
  • AbbVie
  • Abivax
  • Aclaris Therapeutics
  • Akros Pharma/Japan Tobacco
  • Bristol Myers Squibb
  • Genosco/Oscotec
  • Gilead and Galapagos NV
  • GlaxoSmithKline
  • Hope Biosciences
  • Izana Bioscience/Takeda
  • Merck
  • Mesoblast
  • Pfizer/Philogen
  • R Pharm
  • Roche/Genentech
  • Taisho Pharmaceuticals/Ablynx
  • UCB Pharma/PRA HEALTH SCIENCES
  • Viela Bio
Note: Product cover images may vary from those shown
Adroll
adroll